Shares of Insys Therapeutics were on the rise in Thursday’s trading session after the company announced that its epinephrine nasal spray was given fast track designation from the Food & Drug Administration. The FDA has given fast track designation to Insys Therapeutics’ epinephrine nasal spray as an investigational treatment for anaphylaxis, an acute, life-threatening allergic … Continue reading “Insys Therapeutics Skyrockets on FDA Fast Track Designation”
Tag: nasal spray
Biotech & Pharma
FDA Approves The First Drug To Help Stop Nightly Bathroom Visits
The U.S. Food and Drug Administration has just approved the first drug intended on reducing…
March 6, 2017